Screener
ImmunityBio, Inc. IBRX Segment Reporting — Loss on equity method investment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: ImmunityBio, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:24 PM EST
- Fiscal year
- FY2025
- Accession
- 0001326110-26-000030
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Change in fair value of warrant liabilities | 49,089 | 19,955 | (47,600) |
| Change in fair value of related-party convertible note | (42,773) | 43,472 | (36,203) |
| Change in fair value of derivative liabilities | 6,398 | 13,477 | — |
| Loss on equity method investment | — | — | (7,549) |
| Other expense, net | (2,174) | (15) | (2,223) |
| Total other expense, net | (95,580) | (69,463) | (221,642) |
| Loss before income taxes and noncontrolling interests | (351,607) | (413,645) | (583,892) |
| Income tax benefit | 135 | — | 40 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s segment reporting — loss on equity method investment?
- ImmunityBio, Inc. (IBRX) reported segment reporting — loss on equity method investment of $0 in Q4 2025.
- What is the long-term trend for ImmunityBio, Inc.'s segment reporting — loss on equity method investment?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s segment reporting — loss on equity method investment has grown at a -100.0% compound annual growth rate (CAGR), from -$7.55M to $0.
- What does segment reporting — loss on equity method investment mean?
- This metric captures the company's share of losses from investments in entities where it exercises significant influence but does not have full control. It reflects the financial performance of joint ventures or minority stakes held by the business segment. Investors monitor this to assess the health of strategic partnerships and the potential for future equity-based losses.
Ask your AI about ImmunityBio, Inc.'s segment reporting — loss on equity method investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude